SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Hepatitis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who started this subject9/13/2004 9:19:52 AM
From: nigel bates  Read Replies (1) of 312
 
InterMune Signs Agreement with Chiron Corporation to License Access to Hepatitis C Genome

BRISBANE, Calif., Sept. 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) today announced that it has entered into a nonexclusive agreement with Chiron Corporation granting InterMune a license to discover, develop and commercialize small molecule therapeutic agents against certain hepatitis C (HCV) targets that are covered by patents owned by Chiron.

This license directly supports the drug discovery program that InterMune began developing with Array BioPharma Inc. in 2002. Since the establishment of the collaboration, InterMune and Array BioPharma have identified and characterized several highly potent preclinical protease inhibitor candidates with improved in vivo bioavailability over competitive small molecule compounds. InterMune will be presenting data on these HCV protease inhibitor candidates at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston in October.

"This license agreement with Chiron will allow us to develop our protease inhibitor program to its full potential. Protease inhibitors represent one of the most promising new classes of drugs for HCV and we are excited to be at the forefront of this research," stated Dan Welch, InterMune's CEO and President. "Our agreement with Chiron is the latest of many key steps toward our goal of becoming a leader in the development and commercialization of innovative medicines for hepatology. In addition to our cutting edge small molecule research program, we are committed to advancing our robust and late stage HCV pipeline and growing our marketed brand, Infergen® (interferon alfacon-1) for HCV."...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News